Surgical Diagnosis and Treatment of Primary Retroperitoneal Liposarcoma - PubMed (original) (raw)
Surgical Diagnosis and Treatment of Primary Retroperitoneal Liposarcoma
Jie Chen et al. Front Surg. 2021.
Abstract
Background: Primary retroperitoneal liposarcoma (PRPLS) is the most common soft tissue sarcoma of the retroperitoneum with high recurrence rate and short overall survival (OS). Methods: A retrospective review of 51 patients with PRPLS, treated between September 1, 2009 and November 30, 2020, was conducted to evaluate clinical outcomes of PRPLS resection. Patient demographics, histopathologic subtypes, overall survival (OS), progression-free survival (PFS), disease recurrence rate, and tumor stage were reviewed and analyzed. Univariate analysis was done to identify factors potentially affecting OS and PFS of PRPLS patients. Multivariate Cox proportional hazards analysis was used to evaluate the impact of various clinicopathological factors on OS and PFS of PRPLS patients. Results: Fifty-one PRPLS patients (28 Males, 23 Females; mean age 56.25 years) were evaluated. There was no significant effect of age, gender, contiguous organ resection, degree of differentiation and tumor size on the OS and PFS of the patients. Univariate analysis showed that negative surgical margin and early tumor stage significantly correlated with OS and PFS (all P < 0.001). Multivariate analysis showed that tumor stage [hazard ratio (HR) = 1.177, P = 0.001] was an independent predictors of poor progression-free survival, and surgical margins [HR = 4.0674 P = 0.038] and tumor stage [HR = 1.167 P = 0.001] were identified as independent predictors of poor overall survival. Conclusion: Negative surgical margin is a prognostic factor of OS, and can prolong the postoperative survival time of PRPLS patients. Tumor stage is a prognostic factor for OS and PFS, and can influence the survival of PRPLS patients. Earlier tumor stages of PRPLS are associated with significantly better outcomes.
Keywords: disease-free survival; management; overall survival; primary retroperitoneal liposarcoma; surgical diagnosis.
Copyright © 2021 Chen, Hang, Gao and Huang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Figure 1
Overall survival: the median OS was 48.5 months and the 3- and 5-year OS were 62 and 38%.
Figure 2
Progression-free survival: the median PFS was 23 months and the 3- and 5-year PFS were 66.2 and 42.3%.
Similar articles
- A retrospective, single-center cohort study on 65 patients with primary retroperitoneal liposarcoma.
Wu YX, Liu JY, Liu JJ, Yan P, Tang B, Cui YH, Zhao YL, Shi Y, Hao YX, Yu PW, Qian F. Wu YX, et al. Oncol Lett. 2018 Feb;15(2):1799-1810. doi: 10.3892/ol.2017.7533. Epub 2017 Dec 5. Oncol Lett. 2018. PMID: 29434876 Free PMC article. - Expression of fibroblast growth factor receptor substrate 2 (FRS2) in primary retroperitoneal liposarcoma and its clinical implications.
Chen WD, Miao CL. Chen WD, et al. Eur Rev Med Pharmacol Sci. 2023 Jul;27(13):6273-6281. doi: 10.26355/eurrev_202307_32987. Eur Rev Med Pharmacol Sci. 2023. PMID: 37458641 - Predictive factors and a novel nomogram for recurrence of primary retroperitoneal liposarcoma: Comprehensive analysis of 128 cases.
Yu ZY, Gao JW, Liu N, Zhou SX, Zhao XD, Li PY. Yu ZY, et al. Oncol Lett. 2023 Apr 28;25(6):257. doi: 10.3892/ol.2023.13843. eCollection 2023 Jun. Oncol Lett. 2023. PMID: 37485421 Free PMC article. - Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors.
Hollon T, Nguyen V, Smith BW, Lewis S, Junck L, Orringer DA. Hollon T, et al. J Neurosurg. 2016 Aug;125(2):410-8. doi: 10.3171/2015.7.JNS151187. Epub 2016 Jan 8. J Neurosurg. 2016. PMID: 26745489 Review. - Synovial sarcoma in children: surgical lessons from a single institution and review of the literature.
Andrassy RJ, Okcu MF, Despa S, Raney RB. Andrassy RJ, et al. J Am Coll Surg. 2001 Mar;192(3):305-13. doi: 10.1016/s1072-7515(00)00806-1. J Am Coll Surg. 2001. PMID: 11245372 Review.
Cited by
- Primary retroperitoneal liposarcoma: a rare case report.
Wang S, Han X, Liu S, Xu G, Li J. Wang S, et al. J Int Med Res. 2021 Dec;49(12):3000605211063085. doi: 10.1177/03000605211063085. J Int Med Res. 2021. PMID: 34878928 Free PMC article. - Phosphorylation of IWS1 by AKT maintains liposarcoma tumor heterogeneity through preservation of cancer stem cell phenotypes and mesenchymal-epithelial plasticity.
Wang Y, Zhang H, La Ferlita A, Sp N, Goryunova M, Sarchet P, Hu Z, Sorkin M, Kim A, Huang H, Zhu H, Tsung A, Pollock RE, Beane JD. Wang Y, et al. Oncogenesis. 2023 May 26;12(1):30. doi: 10.1038/s41389-023-00469-z. Oncogenesis. 2023. PMID: 37237004 Free PMC article. - Giant Retroperitoneal Liposarcoma: Correlation Between Size and Risk for Recurrence.
Marjiyeh-Awwad R, Mansour S, Khuri S. Marjiyeh-Awwad R, et al. World J Oncol. 2022 Oct;13(5):244-248. doi: 10.14740/wjon1528. Epub 2022 Oct 22. World J Oncol. 2022. PMID: 36406196 Free PMC article. Review. - The pyroptosis-related signature predicts prognosis and influences the tumor immune microenvironment in dedifferentiated liposarcoma.
Chen W, Cheng J, Cai Y, Wang P, Jin J. Chen W, et al. Open Med (Wars). 2024 Jan 9;19(1):20230886. doi: 10.1515/med-2023-0886. eCollection 2024. Open Med (Wars). 2024. PMID: 38221934 Free PMC article. - Retroperitoneal liposarcoma with pancreatic metastasis and gastric cancer: a case report.
Abe N, Hikichi T, Waragai Y, Takahashi Y, Kobashi R, Yanagita T, Kumakawa H, Watanabe K, Kobayakawa M, Ohira H. Abe N, et al. Clin J Gastroenterol. 2023 Apr;16(2):164-170. doi: 10.1007/s12328-022-01742-1. Epub 2022 Dec 19. Clin J Gastroenterol. 2023. PMID: 36534319
References
- Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. Available online at: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-O... (accessed April 3, 2021).
LinkOut - more resources
Full Text Sources